Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Early prediction of treatment outcomes represents an essential step towards increased treatment efficacy and survival in patients with hepatocellular carcinoma (HCC). In this study, we performed two-dimensional electrophoresis (2-DE) followed by protein profiling to identify biomarkers predictive of therapeutic outcomes in patients with HCC who received liverdirected therapy (LDTx) involving local radiotherapy (RT), and studied the underlying mechanisms of the identified proteins. Materials and Methods 2-DE analysis was conducted by pooling sera from patients with a good or poor prognosis; serum proteomic profiles of the two groups were compared and analyzed using matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Identified proteins were confirmed via enzyme-linked immunosorbent assay. An invasion assay was performed after overexpression and knockdown of target protein in Huh7 cells. Results Levels of inter-alpha inhibitor H4 (ITIH4), fibrinogen gamma chain, keratin 9/1 complex, carbonic anhydrase I, and carbonmonoxyhemoglobin S were changed by more than 4-fold in response to LDTx. In particular, pre-LDTx ITIH4 expression was more than 5-fold higher in patients with a good prognosis, compared to patients with a poor prognosis. The migration ability of Huh7 cells was significantly suppressed and enhanced by ITIH4 overexpression and knockdown, respectively. The tumors of patients with HCC and a good prognosis expressed high levels of ITIH4, compared to those of patients with a poor prognosis. Conclusion Taken together, ITIH4 may be a potential therapeutic target that could inhibit cancer metastasis, as well as a prognostic marker for patients with HCC who are receiving LDTx.
Abstract
Purpose Early prediction of treatment outcomes represents an essential step towards increased treatment efficacy and survival in patients with hepatocellular carcinoma (HCC). In this study, we performed two-dimensional electrophoresis (2-DE) followed by protein profiling to identify biomarkers predictive of therapeutic outcomes in patients with HCC who received liverdirected therapy (LDTx) involving local radiotherapy (RT), and studied the underlying mechanisms of the identified proteins. Materials and Methods 2-DE analysis was conducted by pooling sera from patients with a good or poor prognosis; serum proteomic profiles of the two groups were compared and analyzed using matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Identified proteins were confirmed via enzyme-linked immunosorbent assay. An invasion assay was performed after overexpression and knockdown of target protein in Huh7 cells. Results Levels of inter-alpha inhibitor H4 (ITIH4), fibrinogen gamma chain, keratin 9/1 complex, carbonic anhydrase I, and carbonmonoxyhemoglobin S were changed by more than 4-fold in response to LDTx. In particular, pre-LDTx ITIH4 expression was more than 5-fold higher in patients with a good prognosis, compared to patients with a poor prognosis. The migration ability of Huh7 cells was significantly suppressed and enhanced by ITIH4 overexpression and knockdown, respectively. The tumors of patients with HCC and a good prognosis expressed high levels of ITIH4, compared to those of patients with a poor prognosis. Conclusion Taken together, ITIH4 may be a potential therapeutic target that could inhibit cancer metastasis, as well as a prognostic marker for patients with HCC who are receiving LDTx.
참고문헌 (17)
- Park JW, "Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma", J Hepatol, 56, pp.1336~1342 (2012)[DOI]
- Llovet JM, "The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma", Liver Transpl, 10(2 Suppl 1), pp.S115~S120 (2004)[DOI]
- Duffy MJ, "A personalized approach to cancer treatment: how biomarkers can help", Clin Chem, 54, pp.1770~1779 (2008)[DOI]
- Baumann M, "Radiation oncology in the era of precision medicine", Nat Rev Cancer, 16, pp.234~249 (2016)[DOI]
- [URL]
- Sargent DJ, "Clinical trial designs for predictive marker validation in cancer treatment trials", J Clin Oncol, 23, pp.2020~2027 (2005)[DOI]
- Bialecki ES, "Diagnosis of hepatocellular carcinoma", HPB (Oxford), 7, pp.26~34 (2005)[DOI]
- Henry NL, "Cancer biomarkers", Mol Oncol, 6, pp.140~146 (2012)[DOI]
- Gao HJ, "Quantitative proteomic analysis for high-throughput screening of differential glycoproteins in hepatocellular carcinoma serum", Cancer Biol Med, 12, pp.246~254 (2015)
- Kim KH, "Therapeutic benefit of radiotherapy in huge (<TEX>$\geq$<", TEX>10 cm) unresectable hepatocellular carcinoma, 2014, pp.34, 784~794
- Shevchenko A, "Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels", Anal Chem, 68, pp.850~858 (1996)[DOI]
- Choi BK, "Single-step perfusion chromatography with a throughput potential for enhanced peptide detection by matrix-assisted laser desorption", ionization-mass spectrometry, 2003, pp.3, 1955~1961
- Chandler KB, "Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4", J Proteome Res, 13, pp.3314~3329 (2014)[DOI]
- Kobayashi H, "Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro", J Biol Chem, 270, pp.8361~8366 (1995)[DOI]
- Hamm A, "Frequent expression loss of inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis", BMC Cancer, 8, pp.25~ (2008)[DOI]
- Noh CK, "Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virusassociated hepatocellular carcinoma", Clin Biochem, 47, pp.1257~1261 (2014)[DOI]
- Huang L, "A serum-derived hyaluronanassociated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor", J Biol Chem, 268, pp.26725~26730 (1993)